Influence of hormone replacement therapy in antioxidant enzymes activity, strontium and iron levels, and bone metabolism in women. / INFLUÊNCIA DA TERAPIA DE REPOSIÇÃO HORMONAL SOBRE A ATIVIDADE DE ENZIMAS ANTIOXIDANTES, NÍVEIS DE ESTRÔNCIO E FERRO, E METABOLISMO ÓSSEO EM MULHERES

AUTOR(ES)
DATA DE PUBLICAÇÃO

2006

RESUMO

Natural loss of estrogen occurring in menopausal process may contribute to various health problems many of them possibly related to oxidative stress. Decrease in circulating estrogen levels and increase in follicle stimulating hormone levels (FSH) in menopausal status are related with decrease in bone mineral density. Hormone replacement therapy (HRT) is the most common treatment to attenuate menopausal disturbances and strontium (Sr) and iron (Fe) have been suggested to influence to bone metabolism. The objectives of this study was to evaluate the influence of HRT on the activity of antioxidant enzymes (SOD, CAT, and GPx) and lipid peroxidation (TBARS) in menopausal women and to determine blood strontium and iron levels and their relationship with bone mineral density and biochemical parameters in pre and postmenopausal women with or without HRT. Blood antioxidant enzyme activities were determined in premenopausal (n=18) and in postmenopausal healthy women without (n=21) or with HRT (n=19) (mean ages: 47, 59, and 57, respectively). Whole blood Sr and Fe levels were determined by spectrometric methods (inductively coupled plasma mass spectrometry - ICP-MS and inductively coupled plasma optical emission spectrometry - ICP-OES, respectively) in premenopausal (n=17) and postmenopausal women without (n=20) or with HRT (n=19) (mean ages: 47, 60 and 57 years, respectively). Bone mineral density (BMD) was evaluated at the lumbar spine (BMD L1-L4) and femoral neck (BMD femur) by dual energy X-ray absorptiometry (DEXA). TBARS, CAT, and GPx activity were not significantly different among the groups of study. However, SOD activity was significantly lower in postmenopausal women without HRT (0.680.04 U/mg Hb) when compared both to premenopausal women (0.910.04 U/mg Hb) and to postmenopausal women with HRT (0.890.07 U/mg Hb). SOD activity was positively correlated to the duration of HRT in the postmenopausal groups (r=0.33, p<0.05). Blood Sr and Fe levels in premenopausal (33.663.57 g L-1 and 502.0919.90 mg L-1, respectively) and postmenopausal women without (31.472.58 g L-1 and 523.659.91 mg L-1, respectively) or with HRT (29.743.02 g L-1 and 540.3020.24 mg L-1, respectively) were not significantly different among study groups. BMD L1-L4 and BMD femur were significantly higher in premenopausal women (1.050.23 and 0.840.02 g/cm2, respectively) when compared both to postmenopausal women without (0.900.37 and 0.750.02 g/cm2, respectively) and to postmenopausal women with HRT (0.940.04 and 0.740.02 g/cm2, respectively). However, BMD had no relationship with blood metal levels, but was negatively influenced by FSH levels (β=-0.47, p<0.01 for BMD L1-L4 and β=-0.42, p<0.01 for BMD femur) and age (r=-0.48, p<0.01 for BMD L1-L4 and r=-0.38, p<0.01 for BMD femur). We concluded that HRT antagonizes the decrease of SOD activity that occurs after menopause, suggesting that HRT may play a beneficial role in the protection against oxidative stress. It was also shown that the physiologic whole blood Sr and Fe levels had no significant effect in BMD or other biochemical parameters in pre and postmenopausal women. BMD decreased with the increased in FSH levels and with aging.

ASSUNTO(S)

menopause iron hormonal replacement therapy enzimas antioxidantes strontium estrôncio bone mineral density terapia de reposição hormonal antioxidant enzymes ferro menopausa bioquimica densidade mineral óssea

ACESSO AO ARTIGO

Documentos Relacionados